Northwestern University Identifies Novel Protein Biomarker and Synthetic Drug Candidate to Combat Schizophrenia Cognitive Deficits

Scientists identify a novel protein biomarker and synthetic drug SEAD1 to treat cognitive symptoms in schizophrenia. Discover the future of precision psychiatry.

By: AXL Media

Published: Mar 19, 2026, 12:18 PM EDT

Source: Information for this report was sourced from Northwestern University

Addressing the "Unmet Need" in Psychiatric Care

While existing antipsychotic medications are effective at dampening "positive" symptoms like hallucinations and delusions, they offer almost no relief for the cognitive deficits that define schizophrenia for millions. Symptoms such as disorganized thinking and executive dysfunction often prevent patients from maintaining employment or living independently, frequently leading to homelessness or suicidal ideation. A new study from the Northwestern University Feinberg School of Medicine marks a pivot in treatment strategy, focusing on the biological roots of these cognitive impairments rather than just the behavioral manifestations of psychosis.

Discovery of the Cacna2d1 Protein Biomarker

By analyzing the cerebral spinal fluid of over 100 individuals, the research team identified a previously unknown, freely circulating form of the protein Cacna2d1. In patients with schizophrenia, the levels of this protein are markedly lower than in healthy controls. This deficiency is critical because the protein normally acts as a regulator for neural activity; without sufficient levels, brain circuits become "overexcited," leading to the chaotic neural signaling associated with the disorder’s cognitive symptoms.

The SEAD1 Synthetic Protein Intervention

To test a potential cure, the team engineered a synthetic peptide named SEAD1, modeled after the missing protein signal. When injected into the brains of mice specifically bred to model the genetic traits of schizophrenia, SEAD1 successfully rebalanced the overactive circuits. Remarkably, the treatment corrected behavioral problems without the common side effects associated with psychiatric drugs, such as sedation or restricted movement. First author Marc Dos Santos noted that this treatment effectively "rewires" connections in the adult brain by restoring synaptic plasticity, a feature often lost in chronic mental illness.